MRK: Intismeran plus KEYTRUDA cut melanoma recurrence or death risk by 42%

What happened

In patients whose melanoma was removed by surgery (resected stage IIB-IV), adding intismeran to KEYTRUDA cut the risk of the cancer returning or death by 42%, and the risk of distant spread or death by 38%, compared with KEYTRUDA alone.

Confirmed

Global impact / market context

Merck sells KEYTRUDA, so a combination that improves results in earlier-stage melanoma could support its revenue if approved and adopted. The benefit appears as fewer recurrences, which means patients may need less follow-up treatment, potentially affecting costs and demand.

Analyst inference

Investors weigh Merck's dependence on KEYTRUDA against newer options. A 42% reduction in recurrence or death risk, with two-year recurrence-free survival of 82.2% versus 70.0%, is a concrete data point that may shape expectations for this combination's role.

Analyst inference

What to watch

1. Two-year recurrence-free survival, which means time without the cancer returning, was 82.2% with the combination versus 70.0% with KEYTRUDA alone; overall survival follow-up continues. Confirmed
2. Watch whether Merck seeks regulatory approval for this combination in resected stage IIB-IV melanoma, since approval would be needed before broad use in this earlier setting. Proposed
3. Watch whether longer overall survival data confirm the benefit, because improved survival could influence how doctors choose treatments and how investors value Merck's melanoma franchise. Analyst inference

Evidence

• Original source link unavailable